Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Aspirin decreases systemic exposure to clopidogrel through modulation of P-glycoprotein but does not alter its antithrombotic activity.

Clinical pharmacology and therapeutics - 1 Jun 2014

Oh J, Shin D, Lim K S, Lee S, Jung K-H, Chu K, Hong K S, Shin K-H, Cho J-Y, Yoon S H, Ji S C, Yu K-S, Lee H, Jang I-J

Abstract excerpt

Decreased oral clopidogrel absorption caused by induction of intestinal permeability glycoprotein (P-gp) expression after aspirin administration was observed in rats. This study evaluated the effect of aspirin coadministration on the pharmacokinetics/pharmacodynamics of clopidogrel in humans. A single 75-mg dose of clopidogrel was orally administered before and after 2 and 4 weeks of once-daily 100-mg aspirin...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenosine Diphosphate
Share to Aryldialkylphosphatase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aspirin

Share to Clopidogrel

Share to Fibrinolytic Agents

Share to Platelet Aggregation

Share to Platelet Aggregation Inhibitors

Share to Ticlopidine

Source

Identifiers

PMID: 24566733
DOI: 10.1038/clpt.2014.49

Genes

PON1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Aspirin decreases systemic exposure to clopidogrel through modulation of P-glycoprotein but does not alter its antithrombotic activity.PMID 24566733Read ↗

Influence of genetic co-factors on the population pharmacokinetic model for clopidogrel and its active thiol metabolite.Semantic proximity Read ↗

Active metabolite concentration of clopidogrel in patients taking different doses of aspirin: results of the interaction trial.Semantic proximity Read ↗

Effect of an increased clopidogrel maintenance dose or lansoprazole co-administration on the antiplatelet response to clopidogrel in CYP2C19-genotyped healthy subjects.Semantic proximity Read ↗

Clopidogrel Dosing: Current Successes and Emerging Factors for Further Consideration.Semantic proximity Read ↗

Pharmacogenomics of clopidogrel: evidence and perspectives.Semantic proximity Read ↗

Comparison of loading with maintenance dose of clopidogrel on platelet reactivity in Chinese with different CYP2C19 genotypes prior to percutaneous coronary intervention.Semantic proximity Read ↗

Gene variants in responsiveness to clopidogrel have no impact on clinical outcomes in Chinese patients undergoing percutaneous coronary intervention - A multicenter study.Semantic proximity Read ↗

The clinical relevance of the clopidogrel-proton pump inhibitor interaction.Semantic proximity Read ↗

Clopidogrel pharmacodynamics and pharmacokinetics in the fed and fasted state: a randomized crossover study of healthy men.Semantic proximity Read ↗

A Randomized Study of the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Clopidogrel in Three Different CYP2C19 Genotype Groups of Healthy Japanese Subjects.Semantic proximity Read ↗

A Phase 1 Study of Novel Antiplatelet Agent to Overcome Pharmacogenomic Limitations of ClopidogrelSemantic proximity Read ↗

The paraoxonase-1 pathway is not a major bioactivation pathway of clopidogrel in vitro.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.